

Addiction Treatment Starts Here: Behavioral Health



Webinar 1

September 25, 2019

Webinar Reminders

1. Everyone is muted.

- Press *7 to unmute and *6 to re-mute yourself.

2. Remember to chat in questions!

3. Webinar is being recorded and will be sent out via email and posted to the program page!

Agenda

1. Welcome + Objectives
2. NICHQ + Capability Assessment Data: Results and Promising Practices
3. Questions + Answers
4. Upcoming Activities



Welcome + Objectives

Webinar Objectives

- Identify promising practices from peers with capabilities in prescribing buprenorphine, treatment retention, urine toxicology, and staff training and development
- Share common challenges



Results and Promising Practices

Building MAT Capabilities, Learning from Program Data

- We'll highlight promising practices and useful tools, using results from the following NICHQ measures as the catalyst for discussion:
 - Measure B: Buprenorphine Prescribing
 - Measure C: Treatment Retention
 - Measure E: Urine toxicology support in patients prescribed medications for addiction treatment
- We'll also discuss the Staff Training & Development dimension from the IMAT Capability Assessment



Measure B: Volume of Buprenorphine

- Measure Definition:
 - B1: # of clients prescribed buprenorphine = 27
 - B2: # of clients administered naltrexone long-acting injection = 17
 - B3: # of clients prescribed oral naltrexone = 16
 - B4: % of clients prescribed buprenorphine or oral naltrexone, or administered naltrexone long-acting injection of all clients with OUD = 60/61

Fresno
NEW CONNECTIONS



Measure C: Treatment Retention

- Measure Definition:
 - C1: # prescribed buprenorphine/oral naltrexone, or administered naltrexone long-acting injection, who adhered for 6 consecutive months
 - C2: % of all clients prescribed buprenorphine/oral naltrexone or administered naltrexone long-acting injection, who adhered for 6 consecutive months, of all clients prescribed buprenorphine/oral naltrexone or administered naltrexone long-acting injection 6 months prior



Measure E: Urine Toxicology

- Measure Definition:
 - E1: % of clients prescribed buprenorphine/oral naltrexone, or administered naltrexone long-acting injection who received a urine toxicology test within 3 days of starting of all clients starting their medication



IMAT Elements: Staff Training + Development

X-waivered prescribers and other clinicians are actively involved in CME or equivalent continuing education and other advanced learning opportunities focused on medications for OUD, addiction and integrated behavioral health care


All non-clinical program staff, such as administrative and support personnel, have basic training in OUD medications

All non-clinical program staff, such as administrative and support personnel, have basic training in trauma informed care

All staff (clinical and non-clinical) have completed training in empathy and stigma reduction for persons on medications for OUD



Dimension 7: Staff Training & Development - Baseline



Questions + Answers

buprenorphine
ED-Bridge
workflows
referral integration
pairing procedures
MA reading groups
engagement
sustainability
educational workflow interventions
policies
Screening stigma
neuroscience access
training Protocols

Upcoming Activities

Events + Deadlines

- **October 15:** Team quarterly data (2nd submission) and narrative progress reports due
- **October 15:** Webinar 2 (Warm Line, led by Carolyn Chu)
- **November 13:** Tarzana Site Visit
- **November 21:** Webinar 3 (Peer Support Programs)
- **December 11:** Webinar 4 (Staff Training)
- **January 15:** Quarterly data reporting due (3rd submission)
- **January 15:** Motivational Interviewing training (Oakland)
- **January 23:** Motivational Interviewing training (L.A.)
- **March 18 - 19:** Learning Session 2



Closing

Thank you!

For questions contact:

Tammy Fisher
Senior Director
Center for Care Innovations
tammy@careinnovations.org

Sandy Newman
Principal
LSN Health Strategy
sandy@lsnhealthstrategy.com